The invention provides a compound of Formula I, an isomer, a pharmaceutically acceptable salt, or a solvate thereof, and use thereof in manufacture of a medicament for preventing and/or treating a drug-resistant tumor or disease or disorder caused by a drug-resistant bacterium, or use thereof in manufacture of a medicament for preventing and/or treating a tumor, a neurodegenerative disease, an allogeneic graft rejection, or an infection-associated disease or disorder; preferably, the tumor, neurodegenerative disease, allogeneic graft rejection, or infection-associated disease or disorder is a disease or disorder caused by Heat shock protein 70 (Hsp70). The compounds of the invention, which are a class of Hsp70 inhibitors having a novel structure and a high activity, solve the problem concerning drug resistance of tumors, enhance the effect of treating tumors, and provide a new medical strategy for treatment of tumors in clinic. ##STR00001##

The invention concerns a preparation of a compound of formula I,

[Chem 1]

CH.sub.3XCH.sub.2CH.sub.2C(NH.sub.2)COOH  (I) where X represents S or Se, by catalytic conversion of a compound of formula II

[Chem 2]

CH.sub.3XCH.sub.2CH.sub.2C(Y)CN  (II) where X represents S or Se and Y represents NH.sub.2 or OH, when Y represents NH.sub.2, the conversion being carried out in the presence of water and of at least one catalyst comprising at least alumina, titanium dioxide or a mixture thereof, and when Y represents OH, the conversion being carried out in the presence of water, of at least one catalyst comprising at least alumina, titanium dioxide, zirconia or a mixture thereof, and NH.sub.3 or an ammonium salt.

The invention concerns a preparation of a compound of formula I,

[Chem 1]

CH.sub.3XCH.sub.2CH.sub.2C(NH.sub.2)COOH  (I) where X represents S or Se, by catalytic conversion of a compound of formula II

[Chem 2]

CH.sub.3XCH.sub.2CH.sub.2C(Y)CN  (II) where X represents S or Se and Y represents NH.sub.2 or OH, when Y represents NH.sub.2, the conversion being carried out in the presence of water and of at least one catalyst comprising at least alumina, titanium dioxide or a mixture thereof, and when Y represents OH, the conversion being carried out in the presence of water, of at least one catalyst comprising at least alumina, titanium dioxide, zirconia or a mixture thereof, and NH.sub.3 or an ammonium salt.

The present invention relates to: novel selenopsammaplin A and a derivative thereof, which have anticancer activity; a preparation method therefor; and a pharmaceutical composition containing the same as active ingredients and, more specifically, to: a novel compound selenopsammaplin A and a derivative thereof which exhibit more excellent anticancer activity since a disulfide moiety thereof is substituted with diselenide according to research on the structural activity of psammaplin A, which is known to have an effect of inhibiting the growth of cancer cells; a preparation method therefor; and a composition for preventing or treating cancer, containing the same as active ingredients. According to the present invention, the novel selenopsammaplin A and the derivative thereof exhibit excellent anticancer activity on various human cancer cell lines so as to be expected to be effectively usable in a pharmaceutical composition for cancer prevention and treatment.

The present invention relates to: novel selenopsammaplin A and a derivative thereof, which have anticancer activity; a preparation method therefor; and a pharmaceutical composition containing the same as active ingredients and, more specifically, to: a novel compound selenopsammaplin A and a derivative thereof which exhibit more excellent anticancer activity since a disulfide moiety thereof is substituted with diselenide according to research on the structural activity of psammaplin A, which is known to have an effect of inhibiting the growth of cancer cells; a preparation method therefor; and a composition for preventing or treating cancer, containing the same as active ingredients. According to the present invention, the novel selenopsammaplin A and the derivative thereof exhibit excellent anticancer activity on various human cancer cell lines so as to be expected to be effectively usable in a pharmaceutical composition for cancer prevention and treatment.

The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.

A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, R.sup.1 and R.sup.2 represent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and R.sup.1 and R.sup.2 are the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, R.sup.4 represents, for example, C(NH)HN.sub.2, and R.sup.6 represents, for example, a substituted or unsubstituted aryl group].

##STR00001##

A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, R.sup.1 and R.sup.2 represent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and R.sup.1 and R.sup.2 are the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, R.sup.4 represents, for example, C(NH)HN.sub.2, and R.sup.6 represents, for example, a substituted or unsubstituted aryl group].

##STR00001##

A method for preparing 2-hydroxy-4-methylthiobutyric acid (HMTBA) or 2-hydroxy-4-methylselenobutyric acid (HMSeBA) by catalytic conversion of 2-hydroxy-4-methylthiobutyronitrile or 2-hydroxy-4-methylselenobutyronitrile, respectively, where said conversion is carried out in the presence of water and at least one weak acid and one catalyst comprising at least one of alumina, titanium dioxide and zirconia.

A method for preparing 2-hydroxy-4-methylthiobutyric acid (HMTBA) or 2-hydroxy-4-methylselenobutyric acid (HMSeBA) by catalytic conversion of 2-hydroxy-4-methylthiobutyronitrile or 2-hydroxy-4-methylselenobutyronitrile, respectively, where said conversion is carried out in the presence of water and at least one weak acid and one catalyst comprising at least one of alumina, titanium dioxide and zirconia.